Page 38 - MBCA_FULL REPORT_FINAL_FOR_WEB
P. 38

Figure 3: 162 MBC Clinical Trials Assigned to the Hallmarks of Cancer Framework








                                           SUSTAINING PROLIFERATIVE SIGNALING             EVADING GROWTH SUPPRESSORS                    AVOIDING IMMUNE DESTRUCTION                 ENABLING REPLICATIVE IMMORTALITY            TUMOR-PROMOTING INFLAMMATION              ACTIVATING INVASION & METASTASIS                          INDUCING ANGIOGENESIS                          GENOME INSTABILITY AND MUTATION                            RESISTING CELL DEATH                           DEREGULATIN








                                                           95        9

                                                     0                     27

                                                         Active MBC

                                                  1    Clinical Trials          0
                                                           Categorized by the
                                                          Hallmarks of Cancer:
                                                          The Next Generation
                                                     25                      0

                                                            4         1















                       GENOME
                       INSTABILITY AND
                       MUTATION
                       PARP inhibitors                                 ACTIVE CLINICAL TRIAL DETAILS
                       HDAC inhibitors*                               Note: 37 additional trials not targeted or could not be assigned to a hallmark
                       Minor groove of DNA
                       inhibitor (PM01183)  INDUCING   ACTIVATING   TUMOR-             ENABLING
                                       ANGIOGENESIS   INVASION AND   PROMOTING         REPLICATIVE IMMORTALITY
                       RESISTING CELL   VEGF inhibitors  METASTASIS  INFLAMMATION      GRN163L trial halted in MBC in 2013
                       DEATH                          TGF-b inhibitor   Inflammation remains   Other telomerase inhibitors in trials
                       IAP (inhibit apoptosis         (fresolimumab)  of key interest in BC  for hematologic cancers
                       proteins) (LCL161)
                                       SUSTAINING PROLIFERATIVE     EVADING GROWTH SUPPRESSORS  AVOIDING IMMUNE
                       DEREGULATING    SIGNALING                    CDK inhibitors   Agents:   DESTRUCTION
                       CELLULAR        PI3/Akt/mTOR           Hormone-mediated          Palbociclib  18 vaccine
                       ENERGETICS      JAK                             PTEN        LEE011      7 immunomodulators
                       DIG-HIF1 being studied   Notch                       RAF/MEK/ERK/ALK        Y2835219
                       in early BC. Phase II  ERB receptors   Other
                       *does not relate to "Genome Instability and Mutation" hallmark but instead is a modulator of transcription that is not easily  t into any one of the hallmark categories.
                       Abbreviations: BC = breast cancer; BH3 = pro-apoptotic member of the Bcl-2 protein family; anti-CTLA4 mAb = anti–cytotoxic T-lymphocyte
         38            associated protein 4 monoclonal antibody; CDK = cyclin-dependent kinase; DNA = deoxyribonucleic acid; EFGR, ERB = another term
                       for ErbB, the epidermal growth factor receptor protein family; HDAC = histone deacetylase; HGF/c-Met = hepatocyte growth factor/MET
                       proto-oncogene, receptor tyrosine kinase; JAK = Janus kinase family; MBC = metastatic breast cancer; Notch = family of proteins involved
                       in intracellular signaling; PARP = poly-ADP ribose polymerase; PTEN = phosphatase and tensin homolog; RAF/MEK/ERK/ALK = a key cellular
                       signaling pathway; TGF-b = transforming growth factor beta; VEGF = vascular endothelial growth factor.
   33   34   35   36   37   38   39   40   41   42   43